We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

The FDA has started a priority review of Vertex Pharma and CRISPR Therapeutics’ exagamglogene autotemcel (exa-cel) in sickle cell disease (SCD), with a decision on approval due by 8th December.

Intensive chemo is used before treatment with gene-editing medicines, including Vertex's CRISPR Therapeutics-partnered Casgevy (exagamglogene autotemcel), which became the first based on the ...

HHS had argued that Vertex's plan to cover fertility services for some patients that took its gene therapy would violate anti-kickback and inducement laws.

The approval of the first CRISPR-based therapy in late 2023—CRISPR Therapeutics and Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel or exa-cel) for sickle cell disease and β ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has partnered with CRISPR Therapeutics to develop CASGEVY (exagamglogene autotemcel), a gene-edited cell therapy for sickle cell disease (SCD ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne ...

Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics ... CRISPR-based gene-editing therapy, Casgevy (exagamglogene autotemcel), to sickle cell disorder and beta thalassaemia ...

In 2024, BOC received Vertex accreditation for its bone marrow transplant and cellular therapy services, enabling it to provide, as an accredited centre of excellence, CRISPR-based gene-editing ...